landiolol 280 MG (equivalent to landiolol HCl 300 MG) Injection
- RxCUI
- 2712074
- RxNorm name
- landiolol 280 MG (equivalent to landiolol HCl 300 MG) Injection
- Display name
- landiolol 280 MG (equivalent to landiolol HCl 300 MG) Injection
- Full name
- landiolol 280 MG (equivalent to landiolol HCl 300 MG) Injection
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:51
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| RAPIBLYK | LANDIOLOL | AOP Orphan Pharmaceuticals GmbH | 27e7f20f-78a4-f1a9-e063-6394a90ae465 | 2026-06-19 | Warnings, Adverse reactions | 2712074 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 27e7f20f-78a4-f1a9-e063-6394a90ae465 | landiolol 280 MG Injection [PSN] · landiolol 280 MG Injection [SCD] · landiolol 280 MG (equivalent to landiolol HCl 300 MG) Injection [SY] | 3 | 106 | These highlights do not include all the information needed to use RAPIBLYK safely and effectively. See full prescribing information for RAPIBLYK. RAPIBLYK (landiolol) for injection, for intravenous use Initial U.S. Approval: 2024 | 20260427 |
| 411b0949-3a5e-2a4b-e063-6394a90abcbf | landiolol 280 MG Injection [PSN] · landiolol 280 MG Injection [SCD] · landiolol 280 MG (equivalent to landiolol HCl 300 MG) Injection [SY] | 3 | 6 | These highlights do not include all the information needed to use RAPIBLYK ® safely and effectively. See full prescribing information for RAPIBLYK. RAPIBLYK (landiolol) for injection, for intravenous use Initial U.S. Approval: 2024 | 20260213 |